Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

JuveXO® Unveils Verified Exosome Images, Setting a New Standard in Transparency and Scientific Proof in Cosmetics


News provided by

JuveXO®

Apr 22, 2025, 08:23 ET

Share this article

Share toX

Share this article

Share toX

MIAMI, April 22, 2025 /PRNewswire/ -- The scientific team at JuveXO®, one of the most advanced exosome-based solutions available today, is thrilled to announce the first images of exosomes - an incredible achievement that positions JuveXO® at the forefront of biocosmetic discovery. Born from decades of research and innovation by Chief Development & Science Officer (CDSO) Rafael Gonzalez, PhD, a leading figure in cell therapy research, and the scientists behind JuveXO® have fully characterized their exosomes and gone above and beyond to show off their superior exosome product. JuveXO boasts billions of exosomes in each of its vials as well as naturally occurring High Molecular Weight Hyaluronic Acid, Collagen I and III, Glutathione, Biotin, Peptides, and Growth Factors. JuveXO is used topically for hair and skin rejuvenation post aesthetic treatments such as microneedling, RF (radiofrequency) laser, CO2 laser, hair restoration procedures, and chemical peels, enhancing recovery and optimizing results. https://juvexo.com/blogs/articles/breaking-ground-juvexos-first-image-of-an-exosome-a-new-era-in-scientific-visualization

Continue Reading

JuveXO® releases verified exosome images—setting a new benchmark for scientific proof in aesthetics.

Post this
JuveXO exosome image captured by Electron microscopy. This is a Copyrighted Image Owned by Congela Biocosmetics
JuveXO exosome image captured by Electron microscopy. This is a Copyrighted Image Owned by Congela Biocosmetics

But first, what are exosomes? Exosomes are small extracellular vesicles that play a pivotal role in intercellular communication, serving as vehicles for the transport of various biomolecules such as proteins, lipids, and nucleic acids between cells. Exosome technology has garnered significant attention in recent years due to their multifaceted functions and profound implications. JuveXO® is the first biocosmetic company to image exosomes both in frozen vials and following lyophilization using advanced electron microscopy techniques, the correct approach to visualizing an exosome and demonstrating its presence. The ability to visualize exosomes with such precision gives JuveXO® a significant competitive advantage over other players in the biocosmetic sector.

With research on optimal biocosmetic formulations stemming back to 2014, JuveXO® stands out as a distinctive scientific leader in the rapidly evolving field of biocosmetics space. JuveXO®'s umbilical cord lining stem cells (ULSCs) are superior to a standard MSC, were specifically researched and designed for the biocosmetic space—offering optimal results for the skin. 

Chief Development & Science Officer (CDSO) Rafael Gonzalez, PhD of JuveXO® says, "It's a groundbreaking time for all of us at JuveXO® who have dedicated so much research, time and resources perfecting our product. The ability to visualize exosomes with such precision gives JuveXO® a significant competitive advantage over other players in the biocosmetic and aesthetic sectors. The imaging technology that JuveXO® employs represents a significant leap forward in the field of aesthetics, enabling practitioners to see that the product truly does contain exosomes. This helps them trust the products they are providing to patients."

While the ability to visualize exosomes decades ago marked a significant breakthrough in biomedical research for new scientific innovations, many exosome-derived products lacked rigorous validation until recently. Adopting advanced imaging methods has allowed researchers at JuveXO® to deepen their understanding of the exosome. Today, as numerous brands enter the market with claims of including exosomes in their products, the leaders at Congela Biocosmetics, the distributor of JuveXO, are raising the bar for industry transparency. By conclusively proving the presence of exosomes in our products, we invite others to meet this new standard of verification. Our message to the industry is straightforward: "We've shown you ours, now you show us yours."

To prove their presence and integrity in products, JuveXO® has embraced the standards set by the International Society for Extracellular Vesicles (ISEV), which recommends specific techniques for confirming exosome presence, such as nanoparticle tracking analysis, tunable resistive pulse sensing, and electron microscopy amongst other marker expressions that need to be present. Electron microscopy, specifically, allows for the direct observation of exosomes, showcasing their size, shape, and the integrity of their bilipid layers, which are crucial for their functionality.

Utilizing state-of-the-art equipment and methodologies, researchers can accurately observe exosomes on a nanoscale level, pinpointing their presence and concentration in biological samples that lead to deeper scientific insights. By adhering to these ISEV-endorsed techniques and especially employing electron microscopy, JuveXO® not only substantiates the presence of genuine exosomes in their products but also ensures they remain intact and functional from production to delivery. This adherence to the highest scientific standards establishes a new benchmark in product transparency and trust, pioneering a standard that should define the future of regenerative medicine and cosmetic industries alike.

ABOUT JuveXO®
JuveXO® is a high-quality umbilical cord lining stem cell (ULSCs) product that is superior to standard MSC-derived secretome products. We have a patent-pending technology that enables control of the protein type released by ULSCs. With more than ten years of research, JuveXO® has been specially designed to contain high amounts of naturally occurring Types I and III Collagen, Biotin, Gluthathione, Chondroitin Sulfate, Growth Factors, and High-Molecular-Weight Hyaluronic Acid, making JuveXO® the leader in cosmetic use. Our premium serum line is produced from vigorously tested, postnatal ULSCs and is pre-COVID and cell-free. JuveXO® offers a comprehensive exosome portfolio, including:

  • JuveXO® Pro – A multi-dose vial designed for professional aesthetic skincare treatments that boasts 50 billion exosomes per mL.
  • JuveXO® Pro H – Developed specifically for scalp and hair restoration applications with 50 billion exosomes per mL.
  • JuveXO® Lyo – A lyophilized formula with 25 billion exosomes per vial that can be reconstituted to service up to 5 patients, offering greater flexibility and convenience.

JuveXO products are developed in an FDA-registered laboratory which follows good manufacturing practices, ensuring the highest standards of quality, safety, and compliance. Our commitment to excellence is underscored by adherence to rigorous regulatory standards and ethical practices, providing practitioners and consumers with trusted and effective biocosmetic solutions. To find a provider near you, visit JuveXO.com. If you are a physician interested in becoming a provider, visit https://juvexo.com/account/register.

For more information or interviews requests, please contact:
Creative Media Marketing | [email protected]

SOURCE JuveXO®

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.